Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
5 Years
3.4
-191.39%
20%
—
448.55%
80%
—
5 Years
Score3.4
Net Growth-191.39%
Net Trend20%
Net Income Consistency—
Rev Growth448.55%
Rev Trend80%
Revenue Consistency—
Recursion Pharmaceuticals Inc fundamental performance
Between 2021 and 2025, revenue grew from $ 10M to $ 74M and net income went from -$ 178M to -$ 644M. Revenue increased in 80% of the years measured; net income in 20%.
Recursion Pharmaceuticals Inc currently holds a 5-year HDB Score of 3.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 3.29 | — |
1 Year2025-08-12 | $ 5.41 | -39.19% |
5 Years2021-08-12 | $ 22.99 | -85.69% |
All Time2021-04-16 | $ 31.30 | -89.49% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-04-16 |
|---|---|---|---|---|
| Price | $ 3.29 | $ 5.41 | $ 22.99 | $ 31.30 |
| Return | — | -39.19% | -85.69% | -89.49% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 54M | -$ 518M | $ 545M |
| 2025 | $ 74M | -$ 644M | $ 743M |
| 2024 | $ 58M | -$ 463M | $ 594M |
| 2023 | $ 43M | -$ 328M | $ 391M |
| 2022 | $ 39M | -$ 239M | $ 549M |
| IPO2021 | $ 10M | -$ 178M | $ 516M |
Explore beyond RXRX
You're looking at Recursion Pharmaceuticals Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
